TITLE:
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

CONDITION:
Non-Hodgkin's Lymphoma

INTERVENTION:
Interferon Gamma-1b

SUMMARY:

      Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b
      (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with
      progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

      International study with sites in the Czech Republic and Poland
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        -  Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab
             therapy

          -  Patients who were on other therapy including CHOP or radiation

          -  Previous therapy must have concluded 30 days prior to enrollment

          -  Demonstrable CD20-positive tumor population in lymph nodes or bone marrow
      
